XBI Moving Averages Are on the Rise
For the week ended September 11, 2015, the SPDR S&P Biotechnology ETF (XBI) saw a big jump in the number of stocks trading above the 20-day moving average.
How Does XBI Compare to Its 100-Day Moving Average?
The SPDR S&P Biotech ETF (XBI) rose marginally by 0.1% on April 20, 2016. Within XBI, Kite Pharma (KITE) closed at $48.98 on the day.
Why Einhorn’s hedge fund bought a position in Intrexon Corp.
In this seven-part series, we’ll go through some of the main positions Greenlight Capital LP traded this past quarter. Why buy Intrexon Corp. (XON)?
Why Einhorn opened a new position in Tempur Sealy International
Einhorn acquired a small position (0.9%) in Tempur Sealy International Corp in 3Q 2013. Tempur Sealy International posted 111.4% increase in 3Q 2013 net sales.
Why Einhorn sold Greenlight’s position in State Bank Financial
Einhorn exited a 0.5% position in State Bank Financial Corp. He had purchased these shares in 2Q 2011. Net income for 3Q 2013 was $4.3 million.
XBI Remained Stable as the Markets Rallied on Higher Oil Prices
On June 8, the biotech and healthcare sectors had a mixed day and remained sluggish. The SPDR S&P Biotech ETF (XBI) gained 0.1% for the day. XBI has fallen by 16.4% on a year-to-date basis.
Crude Oil’s Implied Volatility Suggests It Could Fall below $50
Yesterday, US crude oil’s implied volatility was 41.3%, 14.4% above its 15-day average.
XBI Holdings Finished Strong as Market Bounced Back on April 13
On April 13, 2016, the SPDR S&P Biotech ETF (XBI) gained 2.4% for the day. XBI outperformed the SPDR S&P 500 ETF (SPY), which gave a return of 1.1%.
XBI Mid-Cap News: Look Who Took a Beating on March 23
Among the 18 mid-cap stocks that XBI holds in its portfolio, 17 declined and only one advanced on March 23. Mid-caps represent ~30% of XBI’s portfolio.
XBI News as of March 16: Mid-Caps Under Pressure
Given selling pressures, XBI’s 18 mid-cap stocks went down marginally on average, losing 0.4% on March 16. Eight stocks advanced while ten stocks declined.
ALNY and XON Drag Down Mid-Cap Stocks Last Week
Alnylam Pharmaceuticals (ALNY) dragged down mid-cap stocks for the week ended September 25. ALNY fell 22.37%, closing at $83.72. It was trading below the 20-day, 50-day, and 100-day moving averages.
Kite Led Top Ten Stocks by Weight in XBI’s Biotechnology Subgroup
Kite Pharma (KITE), which has a weight of 1.17% in the SPDR S&P Biotechnology ETF (XBI), rose 21.94% for the week ended September 11.
IBB Mid-Cap Outperforms XBI Mid-Cap
IBB mid-cap outperformed XBI mid-cap for the week ended September 4, 2015. The IBB top ten mid-cap stocks returned -3.34%, while the XBI top ten mid-cap stocks returned -4.33% for the same period.
ICPT and XON Put Pressure on XBI’s Biotechnology Sector
Intrexon (XON) plummeted by 14.4% after it announced its 2Q15 results. As per the company’s press release, XON’s total revenue was $44.9 million.
IBB Outperforms XBI: Top 10 Mid-Cap Stocks
The top ten mid-cap stocks from IBB outperformed the top ten mid-cap stocks from the SPDR S&P Biotechnology ETF (XBI) for the week ending August 7.
Third Point LLC Holdings hedge fund starts new positions in FDX, GOOG, EQT, XON – 13F Flash
Third Point LLC Holdings, a large U.S. based hedge fund started new positions in Fedex Corp. (FDX), Google Inc. (GOOG), EQT Corp. (EQT), and Intrexon Corp. (XON). Abbreviated financial summaries and metrics for these securities are included below. Detailed analysis and recommendations require a subscription (more information at the bottom of the article). Fedex Corp. […]